Back to team
Paulina joined Omega Funds in January 2019. Prior to joining Omega, Paulina was on the healthcare team at Polaris Partners since 2012. Paulina is currently on the board of IFM Therapeutics and an observer on the boards of Scorpion Therapeutics and Arrakis Therapeutics. Paulina is also involved in the firm’s investments in Beam Therapeutics (NASDAQ: BEAM) and Sana Biotechnology. Paulina previously served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Lyra Pharmaceuticals (NASDAQ: LYRA), Microchips Biotech (acquired by Dare), Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at the Massachusetts Institute of Technology. Paulina was the founding president of the MIT Postdoctoral Association and served on the MIT Intellectual Property Presidential Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. Paulina attended East Carolina University on an athletic scholarship and served as the captain of the women’s varsity tennis team.